TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05345457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill
Description: Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Pill
Description: Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
Study: NCT05207358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroids
Description: 3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.
Study: NCT05775705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DEP and PD-1 antibody
Description: Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
Study: NCT04966429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc
Description: Tablets
Study: NCT06373510

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood collection
Description: Collection of blood before and after a non mandatory vaccination
Study: NCT05804968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital HIV Self Disclosure Intervention
Description: This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
Study: NCT04857710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wide-pulse neuromuscular electrostimulation (WP NMES)
Description: The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional neuromuscular electrostimulation (CONV NMES)
Description: The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control (CONT) modality
Description: Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
Study: NCT05607043

Intervention type: DEVICE
Group type: OTHER
Intervention: Testing for SARS CoV2 RNA
Description: Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
Study: NCT06490315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OkeyMind intervention
Description: The intervention group will receive a one-month mobile psychoeducation program (OkeyMind), which includes both psychoeducation and meditation components, with all content fully automated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait-list control
Description: Participants in the waiting list control group will withhold access to the OkeyMind intervention until after the 3-month follow-up assessment.
Study: NCT05134844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy- Snoezelen
Description: Multi sensory approach in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy- Snoezelen
Description: Multi sensory approach in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snoezelen
Description: Multu Sensory approach on land

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snoezelen
Description: Multu Sensory approach on land
Study: NCT05909423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Intratumoral influenza vaccine treatment, administered via endoscopic procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Single dose pembrolizumab treatment
Study: NCT05559541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: AK119 is an anti-CD73 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
Study: NCT04796896

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study: NCT05439564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
Study: NCT05249751

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessement of serum copeptin by ELISA technique
Description: Assessement of serum copeptin by ELISA technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessement of serum copeptin by ELISA technique
Description: Assessement of serum copeptin by ELISA technique
Study: NCT05549245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal cannula oxygen therapy,
Description: Patients were treated with high-flow nasal cannula oxygen therapy for three nights

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Patients were treated with CPAP for three nights
Study: NCT05649839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: garment
Description: patient randomized in the experimental arm will wear the specially designed garment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: garment
Description: patient randomized in the experimental arm will wear the specially designed garment
Study: NCT05261776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise
Description: Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brisk walk
Description: Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks.
Study: NCT04361175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Each group will be followed up for ovulation by day 12 ovulation monitoring by Transvaginal ultrasound for mature griffian follicle and measure endometrial thickness and volume then day 21 test serum progesterone level to confirm ovulation and if pregnancy occurred confirm by serum pregnancy test at day 35 of the cycle and follow pregnancy till confirmed by fetal pulsation by ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphine Citrate
Description: Clomiphine Citrate
Study: NCT06135259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
Study: NCT05508802

Intervention type: OTHER
Group type: OTHER
Intervention: State Counselor-Coordinated Services
Description: A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers.

Intervention type: OTHER
Group type: OTHER
Intervention: Center Facilitator-Coordinated Services
Description: A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers.
Study: NCT03459651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANS training
Description: In-home computer-based ANS training
Study: NCT05524129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation exercise
Description: Conventional rehabilitation exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: Conventional rehabilitation exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrotherapy
Description: A middle frequency electro-therapy
Study: NCT05516069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Our Healthbox (smart vending machine or interactive dispensing system)
Description: Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
Study: NCT03936127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) Targeted Fusion Biopsy
Description: Ultrasound (US) Targeted Fusion Biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound (US) Targeted Fusion Biopsy
Description: Ultrasound (US) Targeted Fusion Biopsy
Study: NCT04852653

Intervention type: PROCEDURE
Intervention: Supplementary blood samples collection during the normal follow up of the patients
Description: Supplementary blood samples collection during the normal follow up of the patients
Study: NCT05333185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DİABOT (mobile application robot )
Description: DİABOT (mobile application robot ) Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type~1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
Study: NCT05273983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
Study: NCT04718701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib+Toripalimab+Nab-paclitaxel
Description: Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
Study: NCT05342844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.5 mcg
Description: 0.5 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 mcg
Description: 1 mcg/kg
Study: NCT04882800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyric extended wear hearing aid device A
Description: Current commercially available extended wear hearing aid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyric extended wear hearing aid with fitting modification device B
Description: Extended wear hearing aid with fitting modifications
Study: NCT06465056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum toxin application between 3-14 days after direct eyebrow lift surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum toxin application between 3-14 days after direct eyebrow lift surgery.
Study: NCT05704712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentives
Description: Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentives
Description: Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentives
Description: Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentives
Description: Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
Study: NCT06398340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calorie Meal Intervention
Description: Subjects will receive a unhealthy meal high in calorie, sugar and fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calorie Meal Intervention
Description: Subjects will receive a unhealthy meal high in calorie, sugar and fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Calorie Meal Intervention
Description: Subjects will receive a healthy meal with balanced macronutrient, high in vegetables and dietary fibre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Calorie Meal Intervention
Description: Subjects will receive a healthy meal with balanced macronutrient, high in vegetables and dietary fibre
Study: NCT05375305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8554 Injection
Description: SHR8554 Injection; high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8554 Injection
Description: SHR8554 Injection; low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline Solution
Study: NCT04772690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A resource-oriented intervention
Description: The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
Study: NCT05967104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education based on the PLISSIT model
Description: Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.
Study: NCT03953144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synapse 3D Lung Modelling
Description: The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
Study: NCT04964258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-105-a
Description: TAK-105-a subcutaneous solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-105-a Placebo
Description: TAK-105-a placebo-matching solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-105-a Placebo
Description: TAK-105-a placebo-matching solution.
Study: NCT04957173

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle intervention
Description: The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~1. A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~2. A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~3. A maintenance phase of weight loss for 16 weeks.~4. An optional phase of monthly follow-ups for a period of 3 months (no intervention)
Study: NCT05375305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine